Crinetics Pharmaceuticals Q3 EPS $(1.01) Misses $(0.91) Estimate, Sales $346.00K Beat $120.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals reported Q3 losses of $(1.01) per share, missing the analyst consensus estimate of $(0.91) by 10.99%. This is a 29.49% decrease from the same period last year. However, the company's quarterly sales of $346.00K beat the analyst consensus estimate of $120.00K by 188.33%, despite being a 24.45% decrease from last year.
November 07, 2023 | 10:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Crinetics Pharmaceuticals' Q3 earnings per share missed estimates, but sales exceeded expectations.
Crinetics Pharmaceuticals reported a larger than expected loss for Q3, which could negatively impact investor sentiment and the stock price. However, the company's sales exceeded estimates, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100